FDA Issues Guidance On Collection Of Race/Ethnicity Data In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
An FDA draft guidance to aid in collection of standardized race and ethnicity information in clinical trials applies to devices as well as drugs
You may also be interested in...
FDA May Revise MedWatch Reporting Methods For Race, Ethnicity Data
FDA is considering revising the way patient race and ethnicity data are collected on MedWatch adverse event reporting forms
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”